Kristin Mekeel
Concepts (356)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 27 | 2026 | 735 | 3.090 |
Why?
| | Liver Transplantation | 22 | 2025 | 751 | 2.240 |
Why?
| | Organ Transplantation | 7 | 2024 | 244 | 1.270 |
Why?
| | Nephrectomy | 7 | 2026 | 172 | 1.270 |
Why?
| | Liver Diseases | 8 | 2015 | 304 | 1.230 |
Why?
| | Pancreas Transplantation | 7 | 2011 | 70 | 1.190 |
Why?
| | Tissue Donors | 10 | 2026 | 425 | 1.170 |
Why?
| | Graft Survival | 12 | 2026 | 523 | 1.130 |
Why?
| | Laparoscopy | 11 | 2016 | 487 | 1.080 |
Why?
| | Hepatectomy | 8 | 2015 | 256 | 0.980 |
Why?
| | Kidney Failure, Chronic | 7 | 2021 | 589 | 0.950 |
Why?
| | Liver Cirrhosis | 4 | 2022 | 278 | 0.900 |
Why?
| | Living Donors | 7 | 2018 | 216 | 0.890 |
Why?
| | Liver Neoplasms | 7 | 2022 | 776 | 0.880 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2022 | 370 | 0.870 |
Why?
| | Postoperative Complications | 16 | 2024 | 3034 | 0.850 |
Why?
| | Kidney | 6 | 2026 | 1498 | 0.740 |
Why?
| | Hepatic Stellate Cells | 1 | 2020 | 14 | 0.630 |
Why?
| | Renal Nutcracker Syndrome | 1 | 2020 | 7 | 0.610 |
Why?
| | Tissue and Organ Procurement | 5 | 2026 | 305 | 0.610 |
Why?
| | Bile Ducts, Intrahepatic | 4 | 2013 | 62 | 0.590 |
Why?
| | Waiting Lists | 5 | 2020 | 251 | 0.570 |
Why?
| | Students, Medical | 1 | 2023 | 383 | 0.560 |
Why?
| | Cholangiocarcinoma | 4 | 2013 | 110 | 0.540 |
Why?
| | Hepatitis C | 5 | 2025 | 251 | 0.530 |
Why?
| | Bile Duct Neoplasms | 4 | 2013 | 132 | 0.530 |
Why?
| | Cysts | 2 | 2008 | 108 | 0.520 |
Why?
| | Renal Artery | 2 | 2015 | 42 | 0.510 |
Why?
| | Graft Rejection | 7 | 2015 | 516 | 0.500 |
Why?
| | Blood Vessel Prosthesis Implantation | 3 | 2013 | 219 | 0.480 |
Why?
| | Diabetes Mellitus | 4 | 2021 | 1101 | 0.480 |
Why?
| | Hepatitis B | 1 | 2016 | 66 | 0.460 |
Why?
| | Tissue and Organ Harvesting | 1 | 2015 | 69 | 0.440 |
Why?
| | Humans | 81 | 2026 | 146342 | 0.430 |
Why?
| | Retrospective Studies | 28 | 2026 | 17438 | 0.420 |
Why?
| | Vascular Diseases | 2 | 2015 | 252 | 0.420 |
Why?
| | Middle Aged | 38 | 2026 | 36619 | 0.410 |
Why?
| | Transplant Recipients | 4 | 2025 | 177 | 0.410 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2023 | 265 | 0.400 |
Why?
| | Salvage Therapy | 1 | 2015 | 166 | 0.400 |
Why?
| | Adult | 37 | 2026 | 41087 | 0.400 |
Why?
| | Robotic Surgical Procedures | 2 | 2026 | 210 | 0.390 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1221 | 0.380 |
Why?
| | Internship and Residency | 1 | 2023 | 1281 | 0.370 |
Why?
| | Operating Rooms | 2 | 2024 | 145 | 0.350 |
Why?
| | Treatment Outcome | 26 | 2026 | 11821 | 0.350 |
Why?
| | Vena Cava, Inferior | 2 | 2013 | 80 | 0.340 |
Why?
| | Sphincterotomy, Transduodenal | 1 | 2011 | 2 | 0.330 |
Why?
| | Pancreatectomy | 2 | 2011 | 289 | 0.330 |
Why?
| | Viremia | 2 | 2025 | 158 | 0.330 |
Why?
| | Hernia, Ventral | 2 | 2009 | 33 | 0.330 |
Why?
| | Biliary Tract Diseases | 2 | 2012 | 32 | 0.330 |
Why?
| | Ampulla of Vater | 1 | 2011 | 40 | 0.320 |
Why?
| | Hepacivirus | 2 | 2025 | 237 | 0.310 |
Why?
| | Female | 43 | 2026 | 79499 | 0.300 |
Why?
| | Spleen | 1 | 2011 | 503 | 0.290 |
Why?
| | Follow-Up Studies | 14 | 2025 | 5439 | 0.290 |
Why?
| | Rhabdomyolysis | 1 | 2009 | 24 | 0.290 |
Why?
| | Male | 40 | 2026 | 73396 | 0.290 |
Why?
| | Ascites | 1 | 2009 | 48 | 0.290 |
Why?
| | Pancreas | 1 | 2011 | 343 | 0.280 |
Why?
| | Peritonitis | 1 | 2009 | 82 | 0.280 |
Why?
| | Echinococcosis, Hepatic | 1 | 2007 | 2 | 0.270 |
Why?
| | Aged | 19 | 2026 | 26432 | 0.260 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2026 | 244 | 0.260 |
Why?
| | Gallbladder Neoplasms | 1 | 2007 | 20 | 0.260 |
Why?
| | Risk Assessment | 2 | 2016 | 3712 | 0.250 |
Why?
| | Cholecystectomy | 1 | 2007 | 63 | 0.250 |
Why?
| | Bacterial Infections | 1 | 2009 | 247 | 0.250 |
Why?
| | Brain Death | 1 | 2026 | 59 | 0.230 |
Why?
| | Stents | 2 | 2012 | 554 | 0.230 |
Why?
| | Intraoperative Complications | 1 | 2007 | 157 | 0.230 |
Why?
| | Reoperation | 3 | 2020 | 645 | 0.230 |
Why?
| | Polycystic Kidney Diseases | 1 | 2026 | 82 | 0.230 |
Why?
| | Morbidity | 2 | 2023 | 319 | 0.230 |
Why?
| | Mucormycosis | 1 | 2005 | 18 | 0.220 |
Why?
| | Quality Improvement | 2 | 2026 | 1354 | 0.220 |
Why?
| | Liver Failure | 2 | 2017 | 79 | 0.210 |
Why?
| | Portal Vein | 4 | 2016 | 123 | 0.210 |
Why?
| | Beluga Whale | 1 | 2024 | 1 | 0.210 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2005 | 164 | 0.200 |
Why?
| | Incidence | 3 | 2016 | 2936 | 0.190 |
Why?
| | Coinfection | 1 | 2025 | 143 | 0.190 |
Why?
| | Organ Preservation | 1 | 2024 | 123 | 0.190 |
Why?
| | Materia Medica | 1 | 2023 | 1 | 0.190 |
Why?
| | Pancreatic Neoplasms | 1 | 2011 | 944 | 0.190 |
Why?
| | Perfusion | 1 | 2024 | 255 | 0.190 |
Why?
| | Anemia, Sickle Cell | 1 | 2007 | 324 | 0.180 |
Why?
| | Body Weight | 1 | 2007 | 968 | 0.180 |
Why?
| | Surgical Procedures, Operative | 1 | 2026 | 307 | 0.180 |
Why?
| | Morphine Derivatives | 1 | 2022 | 19 | 0.180 |
Why?
| | Tablets | 1 | 2022 | 41 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 78 | 0.170 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 138 | 0.170 |
Why?
| | Acute Kidney Injury | 1 | 2009 | 866 | 0.170 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6073 | 0.170 |
Why?
| | Antiviral Agents | 4 | 2025 | 779 | 0.160 |
Why?
| | Delayed Graft Function | 3 | 2026 | 56 | 0.160 |
Why?
| | Time Factors | 9 | 2023 | 7109 | 0.160 |
Why?
| | Glomerular Filtration Rate | 3 | 2015 | 745 | 0.160 |
Why?
| | Consent Forms | 1 | 2020 | 12 | 0.160 |
Why?
| | Length of Stay | 4 | 2015 | 1358 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2022 | 314 | 0.150 |
Why?
| | Endoscopy, Digestive System | 2 | 2012 | 141 | 0.150 |
Why?
| | Creatinine | 4 | 2015 | 511 | 0.150 |
Why?
| | Pancreaticoduodenectomy | 3 | 2016 | 149 | 0.150 |
Why?
| | Recombination, Genetic | 2 | 1997 | 202 | 0.140 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 306 | 0.140 |
Why?
| | Patient Selection | 3 | 2014 | 728 | 0.140 |
Why?
| | Prognosis | 4 | 2025 | 4351 | 0.140 |
Why?
| | Mycophenolic Acid | 2 | 2010 | 117 | 0.140 |
Why?
| | Vaccination | 2 | 2024 | 1449 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 355 | 0.130 |
Why?
| | Leadership | 1 | 2022 | 414 | 0.130 |
Why?
| | Survival Analysis | 4 | 2010 | 1378 | 0.130 |
Why?
| | Gallbladder Diseases | 2 | 2007 | 12 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 7 | 2016 | 2786 | 0.120 |
Why?
| | Renal Dialysis | 1 | 2021 | 461 | 0.120 |
Why?
| | Granuloma, Plasma Cell | 1 | 2016 | 12 | 0.120 |
Why?
| | Risk Factors | 8 | 2025 | 10921 | 0.120 |
Why?
| | Hypertension, Portal | 2 | 2007 | 66 | 0.120 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1164 | 0.120 |
Why?
| | Recurrence | 5 | 2018 | 1133 | 0.120 |
Why?
| | Iliac Artery | 2 | 2015 | 53 | 0.120 |
Why?
| | Antibodies, Monoclonal | 5 | 2010 | 1512 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 1999 | 530 | 0.120 |
Why?
| | Duodenal Neoplasms | 1 | 2016 | 26 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2009 | 302 | 0.120 |
Why?
| | Antilymphocyte Serum | 3 | 2010 | 55 | 0.120 |
Why?
| | Antibodies, Neoplasm | 3 | 2010 | 34 | 0.110 |
Why?
| | Hyperglycemia | 2 | 2010 | 384 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2015 | 1543 | 0.110 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2015 | 6 | 0.110 |
Why?
| | Survival Rate | 3 | 2016 | 2092 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1408 | 0.110 |
Why?
| | Immunosuppressive Agents | 6 | 2010 | 829 | 0.110 |
Why?
| | Liver | 2 | 2022 | 1864 | 0.110 |
Why?
| | Donor Selection | 1 | 2015 | 66 | 0.110 |
Why?
| | Aged, 80 and over | 7 | 2015 | 8391 | 0.110 |
Why?
| | Kidney Function Tests | 1 | 2015 | 156 | 0.110 |
Why?
| | Family | 2 | 2017 | 690 | 0.100 |
Why?
| | United States | 5 | 2024 | 16136 | 0.100 |
Why?
| | Registries | 2 | 2021 | 2400 | 0.100 |
Why?
| | California | 1 | 2015 | 475 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2022 | 1247 | 0.100 |
Why?
| | Regression Analysis | 2 | 2014 | 999 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2022 | 1210 | 0.100 |
Why?
| | Insulin | 3 | 2010 | 2525 | 0.100 |
Why?
| | Child | 7 | 2020 | 22693 | 0.100 |
Why?
| | Geography | 1 | 2014 | 187 | 0.100 |
Why?
| | Global Health | 1 | 2016 | 403 | 0.090 |
Why?
| | Pregnancy Trimester, Second | 1 | 2013 | 91 | 0.090 |
Why?
| | Pancreatic Ducts | 2 | 2011 | 81 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1408 | 0.090 |
Why?
| | End Stage Liver Disease | 1 | 2014 | 84 | 0.090 |
Why?
| | Young Adult | 7 | 2023 | 14330 | 0.090 |
Why?
| | Surgical Wound Infection | 4 | 2009 | 349 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2018 | 682 | 0.090 |
Why?
| | Hepatocytes | 2 | 2023 | 224 | 0.090 |
Why?
| | Contraindications | 1 | 2011 | 88 | 0.090 |
Why?
| | Splenectomy | 1 | 2011 | 61 | 0.080 |
Why?
| | Aspartate Aminotransferases | 2 | 2012 | 86 | 0.080 |
Why?
| | Bilirubin | 2 | 2012 | 101 | 0.080 |
Why?
| | Surgical Mesh | 2 | 2009 | 54 | 0.080 |
Why?
| | Hospital Mortality | 1 | 2015 | 1051 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 268 | 0.080 |
Why?
| | Cholestasis | 2 | 2012 | 217 | 0.080 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 240 | 0.080 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1412 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4580 | 0.070 |
Why?
| | Sclerosis | 1 | 2009 | 11 | 0.070 |
Why?
| | Hemobilia | 1 | 2009 | 1 | 0.070 |
Why?
| | C-Peptide | 1 | 2010 | 191 | 0.070 |
Why?
| | Atrophy | 1 | 2010 | 199 | 0.070 |
Why?
| | Paracentesis | 1 | 2009 | 16 | 0.070 |
Why?
| | Kidney Tubules | 1 | 2010 | 117 | 0.070 |
Why?
| | HIV Infections | 1 | 2025 | 3215 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 201 | 0.070 |
Why?
| | Physical Endurance | 1 | 2010 | 278 | 0.070 |
Why?
| | Plasmapheresis | 1 | 2009 | 24 | 0.070 |
Why?
| | Inpatients | 2 | 2010 | 540 | 0.070 |
Why?
| | Boronic Acids | 1 | 2009 | 37 | 0.070 |
Why?
| | Isoantibodies | 1 | 2009 | 58 | 0.070 |
Why?
| | Surgical Stapling | 1 | 2008 | 14 | 0.070 |
Why?
| | Intestinal Obstruction | 1 | 2009 | 54 | 0.070 |
Why?
| | Hepatomegaly | 1 | 2008 | 4 | 0.070 |
Why?
| | Drug Overdose | 1 | 2013 | 377 | 0.070 |
Why?
| | Protease Inhibitors | 1 | 2009 | 103 | 0.070 |
Why?
| | Cadaver | 1 | 2009 | 304 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2008 | 103 | 0.070 |
Why?
| | Pyrazines | 1 | 2009 | 94 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 87 | 0.070 |
Why?
| | Pancreatitis | 1 | 2009 | 146 | 0.070 |
Why?
| | Abdominal Pain | 1 | 2009 | 149 | 0.070 |
Why?
| | Pancreatic Diseases | 1 | 2008 | 64 | 0.070 |
Why?
| | Adolescent | 5 | 2016 | 22557 | 0.060 |
Why?
| | Fibrosis | 1 | 2010 | 568 | 0.060 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2007 | 15 | 0.060 |
Why?
| | HLA Antigens | 1 | 2009 | 241 | 0.060 |
Why?
| | Incidental Findings | 1 | 2007 | 81 | 0.060 |
Why?
| | Decompression, Surgical | 1 | 2007 | 115 | 0.060 |
Why?
| | Societies, Medical | 2 | 2024 | 907 | 0.060 |
Why?
| | Diabetic Nephropathies | 1 | 2010 | 320 | 0.060 |
Why?
| | Warm Ischemia | 1 | 2026 | 35 | 0.060 |
Why?
| | Prednisone | 1 | 2007 | 229 | 0.060 |
Why?
| | Tacrolimus | 1 | 2007 | 192 | 0.060 |
Why?
| | Lymph Node Excision | 1 | 2007 | 174 | 0.060 |
Why?
| | Iris Neoplasms | 1 | 2006 | 1 | 0.060 |
Why?
| | Diagnostic Techniques, Digestive System | 1 | 2006 | 12 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2006 | 46 | 0.060 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2006 | 7 | 0.060 |
Why?
| | Treatment Failure | 1 | 2007 | 361 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 164 | 0.060 |
Why?
| | Sirolimus | 1 | 2007 | 282 | 0.060 |
Why?
| | Operative Time | 1 | 2026 | 195 | 0.060 |
Why?
| | Weight Gain | 1 | 2009 | 562 | 0.060 |
Why?
| | Walking | 1 | 2010 | 546 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2006 | 59 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2921 | 0.060 |
Why?
| | Alemtuzumab | 3 | 2010 | 15 | 0.060 |
Why?
| | Polyethylene Glycols | 1 | 2010 | 650 | 0.060 |
Why?
| | DNA Damage | 2 | 1999 | 439 | 0.050 |
Why?
| | Digestive System Surgical Procedures | 1 | 2006 | 115 | 0.050 |
Why?
| | Biopsy | 3 | 2016 | 1075 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3926 | 0.050 |
Why?
| | Adenoma | 1 | 2006 | 210 | 0.050 |
Why?
| | Mice | 2 | 2020 | 18297 | 0.050 |
Why?
| | HIV | 1 | 2025 | 249 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2010 | 2623 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1488 | 0.050 |
Why?
| | Shock, Septic | 1 | 2005 | 230 | 0.050 |
Why?
| | Informatics | 1 | 2022 | 6 | 0.050 |
Why?
| | Animals | 3 | 2024 | 38107 | 0.050 |
Why?
| | Cell Separation | 1 | 2023 | 300 | 0.040 |
Why?
| | Terminology as Topic | 1 | 2024 | 253 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2240 | 0.040 |
Why?
| | Necrosis | 1 | 2022 | 243 | 0.040 |
Why?
| | Prospective Studies | 3 | 2022 | 8123 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2024 | 561 | 0.040 |
Why?
| | Mortality | 1 | 2022 | 375 | 0.040 |
Why?
| | Observer Variation | 1 | 2020 | 356 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 129 | 0.040 |
Why?
| | Quality of Life | 2 | 2010 | 3200 | 0.040 |
Why?
| | Plasmids | 2 | 1997 | 373 | 0.040 |
Why?
| | Cyclins | 1 | 1999 | 77 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2010 | 992 | 0.040 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 96 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2023 | 587 | 0.030 |
Why?
| | Inflammation | 1 | 2010 | 2919 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2023 | 4118 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2009 | 134 | 0.030 |
Why?
| | Rituximab | 2 | 2009 | 208 | 0.030 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 102 | 0.030 |
Why?
| | Allografts | 1 | 2018 | 151 | 0.030 |
Why?
| | Communication | 1 | 2024 | 980 | 0.030 |
Why?
| | Cholangiography | 1 | 2016 | 10 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 193 | 0.030 |
Why?
| | Flow Cytometry | 2 | 1999 | 1163 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2016 | 48 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 1997 | 160 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 2010 | 1036 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 2 | 2010 | 486 | 0.030 |
Why?
| | Ataxia Telangiectasia | 1 | 1996 | 18 | 0.030 |
Why?
| | Cinnamates | 1 | 1996 | 12 | 0.030 |
Why?
| | Child, Preschool | 2 | 2013 | 11913 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 526 | 0.030 |
Why?
| | Cell Cycle | 1 | 1999 | 595 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 1999 | 616 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 1135 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2015 | 38 | 0.030 |
Why?
| | alpha-Glucosidases | 1 | 2015 | 9 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1997 | 882 | 0.030 |
Why?
| | Fibroblasts | 2 | 1999 | 1034 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 1997 | 314 | 0.030 |
Why?
| | Curriculum | 1 | 2022 | 1079 | 0.030 |
Why?
| | Heart | 1 | 2018 | 626 | 0.030 |
Why?
| | Blotting, Western | 1 | 1997 | 1177 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1999 | 740 | 0.030 |
Why?
| | DNA Repair | 1 | 1996 | 255 | 0.020 |
Why?
| | ROC Curve | 1 | 2015 | 617 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2010 | 3930 | 0.020 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2013 | 41 | 0.020 |
Why?
| | Infant | 1 | 2007 | 10114 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1503 | 0.020 |
Why?
| | Hepatoblastoma | 1 | 2013 | 52 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 1998 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2012 | 151 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2012 | 144 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1999 | 1468 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 2010 | 1361 | 0.020 |
Why?
| | Biomarkers | 2 | 2015 | 4340 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2013 | 504 | 0.020 |
Why?
| | Arizona | 1 | 2010 | 81 | 0.020 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2012 | 218 | 0.020 |
Why?
| | Ribavirin | 1 | 2010 | 81 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 6077 | 0.020 |
Why?
| | Medical History Taking | 1 | 2009 | 117 | 0.020 |
Why?
| | Blood Glucose | 2 | 2010 | 2360 | 0.020 |
Why?
| | DNA | 1 | 1996 | 1421 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 517 | 0.020 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 24 | 0.020 |
Why?
| | Ileus | 1 | 2009 | 14 | 0.020 |
Why?
| | Bortezomib | 1 | 2009 | 54 | 0.020 |
Why?
| | Bile Ducts | 1 | 2009 | 66 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2009 | 124 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 3131 | 0.020 |
Why?
| | Hematologic Diseases | 1 | 2009 | 66 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 970 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 211 | 0.020 |
Why?
| | Prosthesis-Related Infections | 1 | 2009 | 100 | 0.020 |
Why?
| | Poisoning | 1 | 2009 | 119 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 628 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 663 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1031 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2009 | 219 | 0.020 |
Why?
| | Acute Disease | 1 | 2010 | 1038 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2009 | 178 | 0.020 |
Why?
| | Radiotherapy, Conformal | 1 | 2007 | 75 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 693 | 0.010 |
Why?
| | Hepatic Artery | 1 | 2006 | 53 | 0.010 |
Why?
| | Microsurgery | 1 | 2006 | 75 | 0.010 |
Why?
| | Angiography | 1 | 2006 | 206 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2113 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2006 | 172 | 0.010 |
Why?
| | Logistic Models | 1 | 2010 | 2126 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 874 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1879 | 0.010 |
Why?
| | Safety | 1 | 2006 | 347 | 0.010 |
Why?
| | Cause of Death | 1 | 2006 | 456 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1888 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2007 | 355 | 0.010 |
Why?
| | Age Factors | 1 | 2009 | 3347 | 0.010 |
Why?
| | Prevalence | 1 | 2009 | 2861 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2006 | 689 | 0.010 |
Why?
| | Neoplasms | 1 | 1997 | 2954 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2458 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 7230 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 1999 | 14 | 0.010 |
Why?
| | Infrared Rays | 1 | 1999 | 23 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1591 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 66 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 104 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 1999 | 230 | 0.010 |
Why?
| | Mice, SCID | 1 | 1999 | 360 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2219 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 1999 | 369 | 0.010 |
Why?
| | Hygromycin B | 1 | 1996 | 3 | 0.010 |
Why?
| | Simian virus 40 | 1 | 1996 | 23 | 0.010 |
Why?
| | Pentosyltransferases | 1 | 1996 | 7 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1996 | 80 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1996 | 137 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2219 | 0.010 |
Why?
| | Cell Nucleus | 1 | 1999 | 584 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1996 | 190 | 0.010 |
Why?
| | Transfection | 1 | 1996 | 916 | 0.010 |
Why?
| | Cell Line | 1 | 1996 | 2814 | 0.000 |
Why?
|
|
Mekeel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|